All In Biotech

Drug Trial Radar · NCT07112872

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Aug 19, 2025

Primary completion

Feb 5, 2028

Study completion Feb 5, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TifeglipronDrug

    Tifeglipron will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.

  • SemaglutideDrug

    Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.

  • PlaceboDrug

    Placebo matching tifeglipron will be taken orally QD during the 30-week treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30Time frame: Baseline to Week 30

Locations

51 sites in 4 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health - Tucson

    Tucson, Arizona · Recruiting

  • Orange County Research Center

    Lake Forest, California · Recruiting

  • Prospective Research Innovations Inc.

    Rancho Cucamonga, California · Recruiting

  • Encompass Clinical Research

    Spring Valley, California · Recruiting

  • Chase Medical Research

    Waterbury, Connecticut · Recruiting

  • Emerson Clinical Research Institute

    Washington D.C., District of Columbia · Recruiting

  • K2 Medical Research South Orlando, LLC

    Clermont, Florida · Active not recruiting

  • Center for Diabetes, Obesity and Metabolism Inc

    Pembroke Pines, Florida · Completed

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia · Active not recruiting

  • Accellacare of Duly Health and Care

    Oak Lawn, Illinois · Active not recruiting

  • Mercury Street Medical Group, PLLC

    Butte, Montana · Withdrawn

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York · Completed

  • Accellacare of Piedmont Healthcare

    Statesville, North Carolina · Recruiting

  • Accellacare of Wilmington, LLC

    Wilmington, North Carolina · Recruiting

  • NexGen Research

    Lima, Ohio · Active not recruiting

  • Tristar Clinical Investigations

    Philadelphia, Pennsylvania · Recruiting

  • Alliance for Multispecialty Research. LLC

    Knoxville, Tennessee · Withdrawn

  • Clinical Research Associates

    Nashville, Tennessee · Completed

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas · Completed

  • Apex Mobile Clinical Research

    Bellaire, Texas · Active not recruiting

  • Velocity Clinical Research

    Dallas, Texas · Completed

  • Velocity Clinical Research (Impact Research Institute)

    Waco, Texas · Withdrawn

  • Chrysalis Clinical Research

    St. George, Utah · Completed

  • Manassas Clinical Research Center

    Manassas, Virginia · Recruiting

  • Obudai Egeszsegugyi Centrum Kft.

    Budapest, Hungary · Completed

  • Qualiclinic Kft.

    Budapest, Hungary · Withdrawn

  • Centrum Medyczne INTERCOR Sp. z o.o.

    Bydgoszcz, Poland · Active not recruiting

  • Pro Familia Altera Sp z o.o.

    Katowice, Poland · Active not recruiting

  • ETG Lublin

    Lublin, Poland · Completed

  • Ekamed sp. z o.o.

    Lublin, Poland · Completed

  • NZOZ METABOLICA Osrodek Badan Klinicznych

    Tarnów, Poland · Active not recruiting

  • ETG Warszawa

    Warsaw, Poland · Completed

  • Centrum Badan Klinicznych

    Wroclaw, Poland · Active not recruiting

  • ETG Zamosc

    Zamość, Poland · Active not recruiting

  • NZOZ Osteo-Medic s.c. A. Racewicz, J.Supronik

    Bialystok, Podlaskie Voivodeship, Poland · Completed

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Pomeranian Voivodeship, Poland · Active not recruiting

  • Centro Medico Teknon

    Barcelona, Spain · Active not recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Active not recruiting

  • Hospital Clinic de Barcelona (Hospital Clinic i Provincial)

    Barcelona, Spain · Active not recruiting

  • Hospital General Universitario Gregorio Maranon (HGUGM)

    Madrid, Spain · Active not recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.